Annette Mense, PA
Physician Assistant · Carthage, MONPI 1992196778
Payments from drug & device makers
Across 175 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$675
- Dexcom, Inc.$350
- Abbott$267
- Boehringer Ingelheim$266
- Amgen$211
- Sanofi-aventis U.S. LLC$180
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,06899%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $675 |
| Dexcom, Inc. | 26 | $350 |
| Abbott | 14 | $267 |
| Boehringer Ingelheim | 16 | $266 |
| Amgen(2 entities) | 11 | $211 |
| Sanofi-aventis U.S. LLC | 9 | $180 |
| Radius Health, Inc. | 6 | $132 |
| Cequr Corporation | 2 | $131 |
| Tandem Diabetes Care, Inc. | 10 | $127 |
| Bayer | 8 | $125 |
| Antares Pharma, Inc. | 5 | $88 |
| Ascendis Pharma Endocrinology Inc | 4 | $84 |
| Lilly USA, LLC | 4 | $73 |
| Medtronic | 4 | $68 |
| Novartis | 3 | $61 |
| BETA Bionics, Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| AstraZeneca | 2 | $44 |
| AbbVie | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $19 |
| IBSA Pharma Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$114
How this compares
$3,087 in reported general payments places this provider in the 85th percentile of 1,380 physician assistant providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 359 | $540,836 |
| Tresiba Flextouch U-200Insulin Degludec | 172 | $272,509 |
| MounjaroTirzepatide | 221 | $252,185 |
| JardianceEmpagliflozin | 177 | $192,756 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 95 | $127,380 |
| TrulicityDulaglutide | 94 | $122,694 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 112 | $114,364 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 106 | $111,006 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $73,474 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 62 | $71,701 |
| FarxigaDapagliflozin Propanediol | 73 | $63,270 |
| Humulin R U-500Insulin Regular, Human | 14 | $59,603 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $56,480 |
| Novolog FlexpenInsulin Aspart | 151 | $44,241 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $39,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Novolog | $675 | $702,335535 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $73 | $401,323361 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Synjardy, Glyxambi | $266 | $277,699264 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $180 | $71,70162 claims |
| AstraZenecaFarxiga | $44 | $63,27073 claims |
| BayerKerendia | $125 | $10,84514 claims |
| AbbVieSynthroid | $40 | $2,16327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Carthage
- Jennifer DavissonKansas City$343K
- Andrew BergLees Summit$245K
- Sileen DowisKansas City$117K
- Daniel BeckSikeston$114K
- Amee RozancO Fallon$101K
- Autumn WillsCape Girardeau$37K
- Kimberly BrownSaint Louis$28K
- Marc ReitznerSpringfield$24K
- Justin AllphinOzark$23K
- Jacqueline CastagnoWentzville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.